Introduction: Immunotherapy has emerged as an essential treatment option in advanced bladder cancer, offering survival benefits in patients who progress after platinum-based chemotherapy (1). Immune checkpoint inhibitors, including pembrolizumab, nivolumab, atezolizumab, and avelumab, have demonstrated durable responses and manageable safety profil